• Publications
  • Influence
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poorExpand
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.
Rapid progress has been made in the development of new diagnostic assays for tuberculosis in recent years. New technologies have been developed and assessed, and are now being implemented. The XpertExpand
Antigen-processing machinery breakdown and tumor growth.
Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been described in tumors of different histology. Murine data suggest that defects in the MHCExpand
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.
Tuberculosis continues to kill 1·4 million people annually. During the past 5 years, an alarming increase in the number of patients with multidrug-resistant tuberculosis and extensivelyExpand
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts.
Recent data for the global burden of disease reflect major demographic and lifestyle changes, leading to a rise in non-communicable diseases. Most countries with high levels of tuberculosis face aExpand
Toxoplasma gondii down‐regulates MHC class II gene expression and antigen presentation by murine macrophages via interference with nuclear translocation of STAT1α 
The obligate intracellular protozoan parasite Toxoplasma gondii is able to establish persistent infections within human and animal hosts. We have shown recently that T. gondii down‐regulatesExpand
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation is a successful treatment for hematologic malignancies and a variety of genetic and metabolic disorders. In the period following stem cellExpand
Drug-resistant tuberculosis: time for visionary political leadership.
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, mostExpand
Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014. WHO estimates 480,000 cases of these were multidrug resistant (MDR).Expand
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.
Tuberculosis is unique among the major infectious diseases in that it lacks accurate rapid point-of-care diagnostic tests. Failure to control the spread of tuberculosis is largely due to ourExpand